C

Chimera Bioengineering

15 employees

Chimera solves the challenges of CARs with drug-responsive gene regulators, which allow us to re-program of the immune system.

Basic info

Industry

biotechnology research

Sectors

Biotechnology
Health Care
drug responsive control systems
Genetics
ribozymes
cellular immunotherapy
RNA engineering / biology
Bioinformatics
CAR T cell therapeutics

Date founded

2015

Funding rounds raised

Total raised

$23M

from 8 investors over 8 rounds

C

Chimera Bioengineering raised $7.5M on April 28, 2022

Investors: Asian Fund for Cancer Research

C

Chimera Bioengineering raised undisclosed on January 1, 2021

Investors: Sand Hill Angels

C

Chimera Bioengineering raised $23M on May 28, 2019

Investors: Life Science Angels

C

Chimera Bioengineering raised undisclosed on January 1, 2019

Investors: Sand Hill Angels

C

Chimera Bioengineering raised undisclosed on August 25, 2017

Investors: Kairos Ventures and Sand Hill Angels

C

Chimera Bioengineering raised undisclosed on November 15, 2016

Investors: The Angels' Forum and Sand Hill Angels

FAQ